Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-108 with or without penpulimab plus chemotherapy in advanced pancreatic ductal adenocarcinoma
CTR20250632Phase 2Active
- Sponsor
- LaNova Medicines
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LM-108 in pancreatic adenocarcinoma (PDAC), sponsored by LaNova Medicines. Started Apr 2025; status: active.
02
Drugs
LM-108
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20250632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250632.